Please ensure Javascript is enabled for purposes of website accessibility

Johnson & Johnson Plans to Stop Selling Talc-Based Baby Powder

By Brian Orelli, PhD – May 20, 2020 at 2:07PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Sales have dropped due to cancer concerns.

On Tuesday, Johnson & Johnson (JNJ 0.33%) announced plans to discontinue sales of talc-based Johnson's Baby Powder as part of a larger reorganization of products sold by the healthcare conglomerate.

The discontinuation of talc-based Johnson's Baby Powder in North America was due to declining sales of the talc-based products as customers worried about the potential to get cancer from the products.

Johnson & Johnson is facing multiple lawsuits over the potential for talcum powder to cause cancer, potentially due to contamination with asbestos. But the company claims that the discontinuation of sales of the product is solely due to declining sales and it "remains steadfastly confident in the safety of talc-based Johnson's Baby Powder." The company has lost quite a few lawsuits, although it's had many of the verdicts reduced or nullified on appeal.

Hands changing a baby's diaper

Image source: Getty Images.

Adding fuel to the fire, in October, Johnson & Johnson recalled a single lot of Johnson's Baby Powder because the Food and Drug Administration had found "sub-trace levels" (no more than 0.00002%) of asbestos contamination in a bottle of the product. Later the company said its test found no sign of asbestos, contrary to what the FDA had found.

Johnson & Johnson plans to sell the current inventory until supplies run out. The company will continue to sell cornstarch-based Johnson's Baby Powder in North America and plans to sell both talc-based and cornstarch-based products in other parts of the world where it claims "there is significantly higher consumer demand for the product."

Brian Orelli has no position in any of the stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Johnson & Johnson Stock Quote
Johnson & Johnson
$166.72 (0.33%) $0.54

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.